

	Compound Name/Code	Phase II	Phase III	Submission	Approval
Neurology	<b>Aricept</b> (Jelly Formulation) JP	*	*	*	*
	<b>Aricept</b> (Vascular Dementia) US	*	*	*	
	<b>Aricept</b> (Sustained Release Formulation) US	*	*	*	
	<b>Aricept</b> (Lewy Body Dementia) JP	*			
	<b>E2007</b> (Epilepsy) US, EU, JP	*1)	*1)		
	<b>E2007</b> (Neuropathic Pain) US, EU	*			
	<b>E2007</b> (Multiple Sclerosis) EU	*			
	<b>E2007</b> (Migraine Prophylaxis) US	*			
	<b>Inovelon</b> (Epilepsy) South Korea	*	*	*	*
	<b>AS-3201</b> (Diabetic Neuropathy) US, EU		*		
	<b>Zonegran</b> (Orally Disintegrating Tablet) EU	*	*	*	
	<b>Zonegran</b> (Pediatric Indication) EU	*	*		
	<b>Zonegran</b> (Epilepsy, Monotherapy) EU	*	*		
	<b>E0302</b> (Amyotrophic Lateral Sclerosis(ALS)) JP		*		
	<b>E2014</b> (Cervical Dystonia) JP	*	*	*	
<b>SEP-190</b> (Insomnia) JP	*	*			
Oncology & Supportive Care	<b>E7389</b> (Breast Cancer) US, EU, JP	*2)	*2)	*2)	
	<b>E7389</b> (Non-Small Cell Lung Cancer) US	*			
	<b>E7389</b> (Prostate Cancer) US, EU	*			
	<b>E7389</b> (Sarcoma) EU	*			
	<b>E7820</b> (Colorectal Cancer) US	*			
	<b>E7080</b> (Thyroid Cancer) US, EU	*			
	<b>MORAb-003</b> (Ovarian Cancer) US	*	*		
	<b>MORAb-009</b> (Mesothelioma) US, EU	*			
	<b>Dacogen</b> (Five-Day Dosing Regimen for MDS) US	*	*	*	
	<b>Dacogen</b> (Acute Myelogenous Leukemia(AML)) US	*	*		
	<b>irofulven</b> (Prostate Cancer) US	*			
	<b>AKR-501</b> (Idiopathic Thrombocytopenic Purpura) US	*			
	<b>AKR-501</b> (Thrombocytopenia associated with liver disease) US	*			
	<b>amolmogene</b> (Cervical Dysplasia) US		*		
<b>Saforis</b> (Oral Mucositis) US	*	*			
Vascular & Immunological Reaction	<b>Humira</b> (Psoriasis) JP	*	*	*	*
	<b>Humira</b> (Crohn's Disease) JP		*	*	
	<b>Humira</b> (Ankylosing Spondylitis) JP	*	*	*	
	<b>Humira</b> (Juvenile Rheumatoid Arthritis) JP	*	*		
	<b>Humira</b> (Inhibition of Structural Damage of Joints) JP	*	*		
	<b>Humira</b> (Ulcerative Colitis) JP		*		
	<b>E5564</b> (Severe Sepsis) US, EU, JP	*	*		
	<b>E5555</b> (Acute Coronary Syndrome) US, EU, JP	*			
	<b>E5555</b> (Atherothrombotic Disease) US, EU, JP	*			
	<b>E6201</b> (Psoriasis) US	*			
	<b>T-614</b> (Rheumatoid Arthritis) JP	*	*		
<b>Tambacor</b> (Tachyarrhythmia in Paediatric Patients) Japan	*	*	*		
Gastro-intestinal Disorders	<b>Pariet</b> (Helicobacter pylori Eradication by Concomitant Therapy) JP	*	*	*	*
	<b>Pariet</b> (Non-erosive GERD) JP	*	*	*	
	<b>Aciphex</b> (Long-Acting Release Formulation) US	*	*		
	<b>Pariet</b> (Additional Dosage for Reflux Esophagitis) JP		*		
	<b>Pariet</b> (Functional-dyspepsia) JP	*			
	<b>Gasmotin</b> (Gastroprokinetic Agent) Asia	*	*	*3)	*3)
Other Therapeutic Areas	<b>KES524</b> (Obesity Management) JP	*	*	*	
	<b>clevudine</b> (Chronic Hepatitis B) Asia	*	*4)	*4)	
	<b>Glufast</b> (Diabetes) Asia	*	*	*5)	*5)

Updated: February 2, 2010

- 1) Phase IIIs for epilepsy indication are ongoing in US and EU. A Phase II is ongoing in Japan.
- 2) Application is under review in Switzerland and Singapore. Phase IIIs for epilepsy indication are ongoing in US and EU. A Phase II is ongoing in Japan.
- 3) Approval was obtained in Philippines. Applications are under review in Malaysia, Indonesia, and Vietnam. Submission is in preparation in four other Asian countries including some ASEAN members.
- 4) Applications are under review in Malaysia, Thailand, Indonesia, and India. Submission is in preparation in two ASEAN countries. A Phase III study is being prepared in China.
- 5) Approval was obtained in Philippines and Thailand. Applications are under review in Malaysia, Indonesia, and Singapore. Submission is in preparation in five ASEAN countries.

·Development progress of MORAb-009 for the treatment of pancreatic cancer has been delisted from the above as Eisai is currently reviewing the future development strategy of the program